Ibrahim Alfayoumi, Asmita Priyadarshini Khatiwada, Surachat Ngorsuraches. Cost-Effectiveness Analysis of Toripalimab Plus Axitinib for Patients with Advanced Renal Cell Carcinoma in the United States. // Clinical Drug Investigation. – 2025. – DOI: 10.1007/s40261-025-01464-5. – URL: https://doi.org/10.1007/s40261-025-01464-5
Ibrahim Alfayoumi, Asmita Priyadarshini Khatiwada, & Surachat Ngorsuraches (2025). Cost-Effectiveness Analysis of Toripalimab Plus Axitinib for Patients with Advanced Renal Cell Carcinoma in the United States. Clinical Drug Investigation. https://doi.org/10.1007/s40261-025-01464-5
Ibrahim Alfayoumi, et al. “Cost-Effectiveness Analysis of Toripalimab Plus Axitinib for Patients with Advanced Renal Cell Carcinoma in the United States.” Clinical Drug Investigation, 2025. doi:10.1007/s40261-025-01464-5.
@article{Alfayoumi2025,
title = {Cost-Effectiveness Analysis of Toripalimab Plus Axitinib for Patients with Advanced Renal Cell Carcinoma in the United States},
author = {Alfayoumi, Ibrahim and Khatiwada, Asmita Priyadarshini and Ngorsuraches, Surachat},
journal = {Clinical Drug Investigation},
year = {2025},
doi = {10.1007/s40261-025-01464-5},
url = {https://doi.org/10.1007/s40261-025-01464-5}
}